Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sanofi ( (SNY) ) has issued an update.
In its Q4 2024 financial results released on January 30, 2025, Sanofi reported a 10.3% growth in sales, fueled by new pharmaceutical launches and significant contributions from products like Dupixent and Beyfortus. The company exceeded its business EPS guidance for 2024 and anticipates strong earnings growth in 2025, supported by increased R&D investments and a sharpened focus on its biopharma business. Sanofi’s strategic goals include divesting a controlling stake in Opella consumer health to streamline operations and concentrate on its core biopharma pursuits, signaling robust future growth prospects.
More about Sanofi
Sanofi is a global biopharmaceutical company based in Paris, France, specializing in pharmaceuticals, vaccines, and consumer healthcare products. It is focused on providing healthcare solutions across various therapeutic areas, including immunology, oncology, and rare diseases, with a strong emphasis on research and development.
YTD Price Performance: 8.22%
Average Trading Volume: 2,395,651
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $133B
See more insights into SNY stock on TipRanks’ Stock Analysis page.
